Shire PLC (SHP.L)

SHP.L on London Stock Exchange

5,290.00GBp
19 Sep 2014
Price Change (% chg)

-30.00p (-0.56%)
Prev Close
5,320.00p
Open
5,365.00p
Day's High
5,380.00p
Day's Low
5,280.00p
Volume
1,996,784
Avg. Vol
3,201,539
52-wk High
5,380.00p
52-wk Low
2,373.00p

SHP.L

Chart for SHP.L

About

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in... (more)

Overall

Beta: 0.62
Market Cap (Mil.): £31,405.75
Shares Outstanding (Mil.): 589.56
Dividend: 2.24
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 27.20 32.84 33.70
EPS (TTM): 1.96 -- --
ROI: 26.16 18.11 17.35
ROE: 37.75 18.82 18.21
Search Stocks

EU to decide on $52 billion AbbVie, Shire deal by Oct. 16

BRUSSELS - European Union competition regulators will decide by Oct. 16 whether to clear U.S. drugmaker AbbVie's 32 billion pounds (51.99 billion US dollar) bid for Irish peer Shire Plc , the European Commission said on Monday.

15 Sep 2014

EU to decide on $52 bln AbbVie, Shire deal by Oct. 16

BRUSSELS, Sept 15 - European Union competition regulators will decide by Oct. 16 whether to clear U.S. drugmaker AbbVie's 32 billion pounds (51.99 billion US dollar) bid for Irish peer Shire Plc, the European Commission said on Monday.

15 Sep 2014

Shire eating disorder drug gets U.S. priority review

LONDON - Shire's hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems.

15 Sep 2014

Shire eating disorder drug gets U.S. priority review

LONDON, Sept 15 - Shire's hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems.

15 Sep 2014

BRIEF-Shire says files with FDA for approval of binge eating disorder drug

* Acceptance for filing with priority review of supplemental new drug application (SNDA) for Vyvanse (Lisdexamfetamine dimesylate) capsules (CII) for adults with binge eating disorder

15 Sep 2014

UPDATE 3-AbbVie profit beats estimates on surging Humira sales

July 25 - AbbVie Inc, which last week announced plans to buy Dublin-based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly earnings on surging sales of its Humira treatment for rheumatoid arthritis.

25 Jul 2014

Actelion CEO seeks to diffuse takeover talk

ZURICH - Actelion Chief Executive Jean-Paul Clozel said he was determined to keep the Swiss biotech company independent, batting away speculation it could become the next takeover target for U.S. firms seeking lower taxes by relocating abroad.

22 Jul 2014

U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal

LONDON - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on Friday in a 32 billion pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain. | Video

18 Jul 2014

AbbVie’s Shire merger backed with 13.5 billion pound bridge loan

LONDON - U.S. drugmaker AbbVie’s 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

RLPC-AbbVie's Shire merger backed with 13.5 bln stg bridge loan

LONDON, July 18 - U.S. drugmaker AbbVie's 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks